Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 15/20 | 0.33 |
| ▸ | F10 | P00742 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5855697 | 0.81 | LMNA (0.36) | LMNAHTTF2F10KDM4E | |
| SCHEMBL29427272 | 0.77 | LMNA (0.43) | LMNAHTTKDM4ETDP1ALDH1A1 | |
| SCHEMBL113414 | 0.77 | LMNA (0.43) | LMNAHTTKDM4ETDP1ALDH1A1 | |
| SCHEMBL14508590 | 0.73 | F2 (0.32) | LMNAHTTF2F10 | |
| SCHEMBL3476708 | 0.72 | LMNA (0.46) | LMNAHTTKDM4ETDP1ALDH1A1 | |
| SCHEMBL2616406 | 0.69 | LMNA (0.48) | LMNAHTTKDM4ETDP1ALDH1A1 | |
| Formic Acid SCHEMBL30297733 | 0.68 | LMNA (0.35) | LMNAHTTF2KDM4ETDP1 | |
| SCHEMBL30630362 | 0.65 | LMNA (0.40) | LMNAHTTKDM4ETDP1ALDH1A1 | |
| SCHEMBL6640541 | 0.65 | LMNA (0.40) | LMNAHTTKDM4ETDP1ALDH1A1 | |
| SCHEMBL4193811 | 0.65 | S1PR1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131668-A1 | 4-oxo-4,6,7,8-Tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds | LES LABORATOIRES SERVIER (FR) | 2009-05-21 | — | — | US | disclosed |
| US-7498330-B2 | 4-oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds | LES LABORATORIES SERVIER (FR) | 2009-03-03 | — | — | US | disclosed |
| US-7326786-B2 | Thiazolinone unsubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1593682-B1 | Derivatives of 4-oxo-4,6,7,8-tetrahydropyrrolo¬1,2-a pyrazine-6-carboxamides, process for their preparation and pharmaceutical compositions thereof | SERVIER LAB (FR) | 2007-11-07 | — | — | EP | disclosed |
| US-20070099927-A1 | Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-05-03 | — | — | US | disclosed |
| US-20070099927-A1 | Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-05-03 | — | — | US | disclosed |
| US-20070099927-A1 | Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-05-03 | — | — | US | disclosed |
| EP-1765817-A1 | THIAZOLINONE UNSUBSTITUTED QUINOLINES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-28 | — | — | EP | disclosed |
| US-7026324-B2 | Thrombin inhibitors | MERCK & CO., INC. (US) | 2006-04-11 | — | — | US | disclosed |
| WO-2006002829-A1 | THIAZOLINONE UNSUBSTITUTED QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-12 | — | — | WO | disclosed |
| WO-2005040137-A1 | AMINOALKYL-PYRAZINONES AND -PYRIDONES AS THROMBIN INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-05-06 | — | — | WO | disclosed |
| EP-1526131-A1 | Aminoalkyl-pyrazinones and -pyridones as thrombin inhibitors | Graffinity Pharmaceuticals Aktiengesellschaft (DE) | 2005-04-27 | — | — | EP | disclosed |
| US-20040097730-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2004-05-20 | — | — | US | disclosed |
| US-20030225131-A1 | Thrombin inhibitors | BURGEY CHRISTOPHER S (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030158218-A1 | Thrombin inhibitors | NANTERMET PHILIPPE G (US) | 2003-08-21 | — | — | US | disclosed |
| EP-1259506-A1 | PYRAZINONE THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2002064211-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002057225-A2 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| US-6387911-B1 | Pyrazinone thrombin inhibitors | MERCK & CO., INC. | 2002-05-14 | — | — | US | disclosed |
| WO-2001038323-A1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2001-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097730-A1 | Thrombin inhibitors | F3, F2, SERPINC1 | LMNA 4332/4885HTT 3320/4885F2 2/4885 |
| US-20030225131-A1 | Thrombin inhibitors | TFPI, SERPINC1, PLAT | LMNA 4157/4885HTT 1856/4885F2 5/4885 |
| US-20090131668-A1 | 4-oxo-4,6,7,8-Tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds | F2, TBXA2R, PDGFRA | LMNA 4143/4885HTT 1958/4885F2 1/4885 |
| US-20030158218-A1 | Thrombin inhibitors | F2, SERPINC1, TFPI | LMNA 3043/4885HTT 1138/4885F2 1/4885 |
| US-20070099927-A1 | Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors | F2, F12, SERPINC1 | LMNA 1027/4885HTT 4348/4885F2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.